InSilico Medicine (HKG:3696) has dosed the first patient in China for a Phase III trial of its treatment for idiopathic pulmonary fibrosis, according to a Thursday bourse filing.
The GENESIS-IPF-3 study will run for 52 weeks, during which researchers will observe data from 320 subjects receiving Rentosertib, the biotechnology company said.
InSilico said the study will determine whether the company's treatment is effective in a larger group over a longer period than the Phase IIa trial.